Laura de Castro, MD
Hematology · Pittsburgh, PANPI 1649353897
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,350 of the $16,381 with a category attached, or 81.5%. Novartis accounts for 94.1% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2019 at $11,833 and has fallen 90.5% since, to $1,122 in 2024.
Across 18 payments — averaging $910.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$15K
- Pfizer$963
Across 83 payments — averaging $11,514 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$477K
- Pfizer$165K
- CSL Behring$157K
- Global Blood Therapeutics, Inc.$156K
- Novo Nordisk Health Care AG$115
What the payments were for
- Consulting fees$13,35081%
- Travel & lodging$1,91012%
- Food & beverage$1,1217%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADAKVEO$14,584
How this compares
$16,381 in reported general payments places this provider in the 75th percentile of 64 hematology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxbrytaVoxelotor | 20 | $238,786 |
| EliquisApixaban | 29 | $15,966 |
| XareltoRivaroxaban | 12 | $7,392 |
| Oxymorphone Hcl ErOxymorphone Hcl | 14 | $5,949 |
| Hydroxyurea | 41 | $1,196 |
| Oxycodone Hcl | 54 | $736 |
| Morphine Sulfate ErMorphine Sulfate | 23 | $407 |
| Hydromorphone Hcl | 11 | $356 |
| Methadone Hcl | 11 | $176 |
| Ondansetron OdtOndansetron | 11 | $116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $963 | $15,96629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 64 hematology providers in Pennsylvania.
Other hematology in Pittsburgh
- Craig SeamanPittsburgh$88K
- Robert KaplanPittsburgh$46K
- Julia XuPittsburgh$33K
- Santhosh SadashivPittsburgh$15K
- Robert RednerPittsburgh$4K
- Neal SpadaPittsburgh$698
- Erika MoorePittsburgh$110
- Olubusola OluwolePittsburgh$41
- Radhakrishnan RamchandrenWest Reading$233K
- Selina LugerPhiladelphia$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.